Prot #HCRN MEL17-309/NU G18M02: Phase II Single-Arm Multi-Center Study of Adjuvant Ipilimumab in Combination with Nivolumab in Subjects with High-Risk Ocular Melanoma

Project: Research project

StatusActive
Effective start/end date10/22/1910/22/22

Funding

  • Hoosier Cancer Research Network, Inc. (Prot #HCRN MEL17-309/NU G18M02)
  • Bristol-Myers Squibb Company (Prot #HCRN MEL17-309/NU G18M02)